Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation.

Lingyan Jin, Tiannan Jiang, Haoyu Gong, Lulu Gong, Yizhen Wang, Ziwei Chen, Peng Liu, Xinghua Qin, Qiangsun Zheng

Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China. · pubmed

Paper

Abstract

Atrial fibrillation (AF) is an age-related disease associated with substantial morbidity and mortality. Although rapamycin stands as a foremost anti-aging therapy with proven efficacy in lifespan extension, a critical gap exists in understanding its impact on aging-induced atrial remodeling and AF susceptibility.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Rapamycin attenuates age-related atrial remodeling and fibrillation by targeting HIF-1α-mediated metabolic dysregulation. This paper is relevant because it investigates the mechanism by which a proven lifespan-extending drug (rapamycin) mitigates a specific age-related pathology, thereby providing mechanistic insight into how mTOR inhibition protects against aging-induced tissue dysfunction.

Author of this paper? Send a correction.